Biotech and Pharmaceuticals Medicine

  • Mounting medical bills are likely to force many people to file for bankruptcy, according to new data from NerdWallet. And even those with insurance are buckling under unpaid bills.

  • Obesity a Disease

    The American Medical Association says obesity should be classified as a disease. CNBC's Bertha Coombs reports AMA's Patrice Harris says the hope is for doctors to be more proactive in treating obese patients.

  • Obamacare's Med School Dilemma

    Discussing the big problems Obamacare creates for hospitals, doctors, and even medical students, with Dr. Beth Haynes M.D. of Benjamin Rush Society, Brian Blank, UNC-Chapel Hill Medical Student.

  • U.S. Supreme Court Building

    Can someone else patent your genes? The Supreme Court is scheduled to rule some time this month on that question. NBCNews.com reports.

  • The Worst Allergy Season Ever

    Allergy season has been getting longer every year for 15 years, with Dr. Michael Foggs of American College of Allergy, Asthma and Immunology; and Stephen Brozak, WBB Securities, discusses the big money in the allergy business.

  • Mayo Clinic's CEO on $5 Billion Expansion

    John Noseworthy, Mayo Clinic president and CEO, discusses what his company is doing to create more jobs, the best opportunities internationally for growth and Obamacare.

  • Rise In Melanoma Treatments

    CNBC's Jackie DeAngelis reports on drug companies making headlines out of the American Society of Clinical Onocology conference. David Risinger of Morgan Stanley discusses the rise in melanoma treatments shown at this year's event.

  • A hospital epidemiologist and a geneticist at the National Institutes of Health Clinical Center in Bethesda, Md.

    Government officials, drug companies and medical experts, faced with outbreaks of antibiotic-resistant "superbugs", are pushing to speed up the approval of new antibiotics, the NYT reports.

  • A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.

  • Leading the Fight Against Cancer

    Bristol-Myers is presenting data on its next-generation drug Nivolumab, which treats tumors, reports CNBC's Bertha Coombs.

  • Searching For a Cancer Breakthrough

    Gilead is taking aim at cancer, and the company is presenting early-stage data at the oncology conference on treatment for blood cancer, reports CNBC's Bertha Coombs.

  • Game Changers: Personalized Medicine

    The cost of sequencing DNA has plunged from $100 million in 2001 to less than $10,000 today. Amit Bhalla, Citi, offers insight on the developing technologies for personalized care.

  • Bird Flu Fears Hit Wall St.

    Morgan Stanley is moving a hedge fund meeting out of China after a new drug resistant bird flu strain causes 36 deaths, reports CNBC's Michelle Caruso-Cabrera.

  • In two big M&A deals, Valeant Pharmaceuticals agreed to buy Bausch & Lomb for $8.7 billion, and AstraZeneca agreed to acquire Omthera Pharmaceuticals for as much as $443 million.

  • Gene Testing: Coming to a Doctor Near You

    Stefan Roever, CEO of Genia, tells CNBC how the company is driving down the cost of gene testing from 1000 to 100 dollars and making the results almost immediate.

  • Dr. Martha Perez examines a patient at Community Health of South Florida.

    A 65-year-old couple retiring this year would need $220,000 on average to cover medical expenses, an 8 percent decrease from last year's estimate. But most people estimate just a fraction of that.

  • Angelina Jolie

    The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.

  • Under President Barack Obama's health care law, where you live could make a huge difference in what you'll pay for medications.

  • Intuitive Surgical Raises Red Flag

    CNBC's Herb Greenberg reports on the question facing Intuitive Surgical. The company alerted hospitals of a potential issue with one of its instruments.

  • Massachusetts has had Romneycare since 2006. And, while it's different in some ways from Obamacare, it offers insight into what's ahead for US health care.